biostudies-literatureUnknown12Lazcano R<h4>Introduction</h4>Undifferentiated pleomorphic sarcoma (UPS) can be associated with a relatively dense immune infiltration. Immune checkpoint inhibitors (anti-PD1, anti-PDL1, and anti-CTLA4) are effective in 20% of UPS patients. We characterize the immune microenvironment of UPS and its association with oncologic outcomes.<h4>Material and methods</h4>Surgically resected UPS samples were stained by immunohistochemistry (IHC) for the following: tumor-associated immune cells (CD3, CD8, CD163, CD20), immune checkpoints (stimulatory: OX40, ICOS; inhibitory: PD-L1, LAG3, IDO1, PD1), and the adenosine pathway (CD73, CD39). Sections were reviewed for the presence of lymphoid aggregates (LA). Clinical data were retrospectively obtained for all samples. The Wilcoxon rank-sum and Kruskal-Wallis teFrontiers in oncology1008484https://www.ebi.ac.uk/biostudies/studies/S-EPMC9597628biostudies-literatureThe immune landscape of undifferentiated pleomorphic sarcoma.PMC9597628Zarzour AMLazcano RGite SRavi VLazar AJLu WCope BTraweek RSLin HYParra ERCarapeto FMehta JScally CPKeung EZBarreto CMSalazar RThirasastr PLivingston JAPatel SConley APBenjamin RZhou JWitt RGWargo JLeung CHWistuba IIIngram DRRoland CLRatan RLudwig JWang WLSolis LAraujo DVu KTSomaiah NNassif EFWani KMfalseThe immune landscape of undifferentiated pleomorphic sarcoma.<h4>Introduction</h4>Undifferentiated pleomorphic sarcoma (UPS) can be associated with a relatively dense immune infiltration. Immune checkpoint inhibitors (anti-PD1, anti-PDL1, and anti-CTLA4) are effective in 20% of UPS patients. We characterize the immune microenvironment of UPS and its association with oncologic outcomes.<h4>Material and methods</h4>Surgically resected UPS samples were stained by immunohistochemistry (IHC) for the following: tumor-associated immune cells (CD3, CD8, CD163, CD20), immune checkpoints (stimulatory: OX40, ICOS; inhibitory: PD-L1, LAG3, IDO1, PD1), and the adenosine pathway (CD73, CD39). Sections were reviewed for the presence of lymphoid aggregates (LA). Clinical data were retrospectively obtained for all samples. The Wilcoxon rank-sum and Kruskal-Wallis te2022-01-01T00:00:00Z20222025-04-22T02:06:02.379Z2025-04-05T20:12:35.125ZS-EPMC95976283631366110.3389/fonc.2022.1008484